Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
17:44
A EU-funded project will test 11 natural solutions for protecting Mediterranean agriculture and forests from drought and fires.
17:39
Oradea has developed the first unified regulation for the access of pets in public and private spaces
17:29
EU opens the competition for up to seven gigafactories of artificial intelligence and investments of over 30 billion euros
17:26
Energy market operators propose transitioning European intraday auctions to a more precise calculation of available capacity between states.
17:13
Airbus was fined £6.4 million in the United Kingdom for violating sensitive technology export regulations.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
